Patents Assigned to The John P. Robarts Research Institute
  • Patent number: 6898453
    Abstract: A method for determining tissue type includes quantitatively determining a tissue blood flow (TBF) by deconvoluting Q(t) and Ca(t), where Q(t) represents a curve of specific mass of contrast, and Ca(t) represents an arterial curve of contrast concentration, and quantitatively determining a tissue blood volume (TBV) by deconvoluting Q(t) and Ca(t). The method also includes quantitatively determining a tissue mean transit time (TMTT) by deconvoluting Q(t) and Ca(t), and quantitatively determining a tissue capillary permeability surface area product (TPS) by deconvoluting Q(t) and Ca(t). The method also includes determining a tissue type based on the TBF, the TBV, the TMTT, and the TPS.
    Type: Grant
    Filed: October 25, 2001
    Date of Patent: May 24, 2005
    Assignee: The John P. Robarts Research Institute
    Inventor: Ting Y. Lee
  • Publication number: 20040110286
    Abstract: This invention provides a system for producing cells of the hematopoietic lineage from embryonic stem cells. Differentiation is conducted in the presence of hematogenic cytokines and other factors listed in the disclosure. The cell population that is obtained is remarkably enriched in CD45 +ve cells, a marker of early hematopoietic precursor with self-renewing capacity. Including a bone morphogenic protein during the differentiation process enhances the ability of the cell population to form secondary colonies. Because of the enormous replicative capacity of embryonic stem cells, this provides an important new commercial source of hematopoietic cells.
    Type: Application
    Filed: December 6, 2002
    Publication date: June 10, 2004
    Applicant: The John P. Robarts Research Institute
    Inventor: Mickie Bhatia
  • Publication number: 20030153082
    Abstract: This invention provides a system for producing cells of the hematopoietic lineage from embryonic stem cells. Differentiation is conducted in the presence of hematogenic cytokines and other factors listed in the disclosure. The cell population that is obtained is remarkably enriched in CD45 +ve cells, a marker of early hematopoietic precursor with self-renewing capacity. Including a bone morphogenic protein during the differentiation process enhances the ability of the cell population to form secondary colonies. Because of the enormous replicative capacity of embryonic stem cells, this provides an important new commercial source of hematopoietic cells.
    Type: Application
    Filed: December 6, 2002
    Publication date: August 14, 2003
    Applicant: The John P. Robarts Research Institute
    Inventor: Mickie Bhatia